FindTrial
Sign In

Detection of Chlamydia trachomatis antibodies in vaginal swabs as an intermediate marker for PID and tubal pathology * pilot study

Detection of Chlamydia trachomatis antibodies in vaginal swabs as an intermediate marker for PID and tubal pathology * pilot study - Pilot study CAT mucosa

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON36428
Enrollment
150
Registered
2011-03-18
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chlamydia PID tubal infertility

Interventions

None listed

Sponsors

RIVM
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In STI-clinics: women who tested positive or negative in a PCR test for (current) genital Chlamydia trachomatis infection and are willing to participate in the study. In fertility clinic: women who tested positive or negative with serum Chlamydia antibody test (CAT).

Exclusion criteria

Exclusion criteria: In STI clinics: women with coinfection HIV, girls under 18 years old. In infertility clinic: women with HIV.

Design outcomes

Primary

MeasureTime frame
To compare the presence and quantity/titres of IgG antibodies findings with the health status of the patients regarding current (vaginal) Chlamydia infections, history of prior Chlamydia infections, in lower genital tract (vagina, cervix) or higher parts (pelvic, ovaria: PID) and fertility-related problems (tubal pathology).—

Secondary

MeasureTime frame
Depending on the outcomes of this pilot, we aim to set-up a larger study to investigate the prevalence of these antibodies in vaginal samples and the risk for PID prospectively in a dual cohort of women, screened and unscreened.—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)